<qa>  What is the primary objective of the study?Secondary objectives include 1 characterizing progression-free survival PFS; 2 determining response duration RD; 3 characterizing the effect of MDX-060 on health-related Quality of Life QoL; 4 evaluating patients with pcALCL using an adaption of the NCI Response Criteria for NHL; 5 characterizing the immunogenicity of MDX-060; 6 characterizing the safety of MDX-060; and 7 determining the best objective response rate BORR during the Maintenance Phase of the study. 